HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael A Nader Selected Research

Cocaine-Related Disorders (Cocaine Addiction)

1/2021Chronic levetiracetam (Keppra®) treatment increases the reinforcing strength of cocaine in rhesus monkeys.
11/2016Neural Correlates of Exposure to Cocaine Cues in Rhesus Monkeys: Modulation by the Dopamine Transporter.
1/2016Effects of abstinence from chronic cocaine self-administration on nonhuman primate dorsal and ventral noradrenergic bundle terminal field structures.
4/2015Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm.
3/2015Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.
1/2015Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys.
9/2014PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations.
1/2014Environmental modulation of drug taking: Nonhuman primate models of cocaine abuse and PET neuroimaging.
6/2013Effects of chronic methylphenidate on cocaine self-administration under a progressive-ratio schedule of reinforcement in rhesus monkeys.
2/2013Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael A Nader Research Topics

Disease

25Cocaine-Related Disorders (Cocaine Addiction)
01/2021 - 02/2002
11Substance-Related Disorders (Drug Abuse)
01/2020 - 11/2004
5Cognitive Dysfunction
01/2021 - 06/2006
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2022 - 02/2009
2Neuroblastoma
01/2022 - 04/2021
2Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
09/2013 - 11/2012
1Neuroinflammatory Diseases
01/2022
1Alzheimer Disease (Alzheimer's Disease)
12/2020
1Parkinson Disease (Parkinson's Disease)
03/2019
1Labyrinthitis (Otitis Interna)
04/2018
1Ataxia (Dyssynergia)
04/2018
1Marijuana Abuse (Cannabis Abuse)
06/2017
1Body Weight (Weight, Body)
04/2016
1Respiratory Insufficiency (Respiratory Failure)
01/2016
1Gambling (Pathological Gambling)
08/2014
1Sleep Deprivation
09/2013
1Tobacco Use Disorder (Nicotine Dependence)
05/2010
1Hyperthyroidism
03/2008
1Hypothermia
10/2007
1Genetic Predisposition to Disease (Genetic Predisposition)
08/2005

Drug/Important Bio-Agent (IBA)

21Cocaine (Cocaine HCl)IBA
01/2022 - 11/2002
11Dopamine (Intropin)FDA LinkGeneric
11/2016 - 08/2006
7Pharmaceutical PreparationsIBA
01/2020 - 08/2005
4Dopamine D3 ReceptorsIBA
07/2015 - 06/2005
3N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA
03/2008 - 10/2007
2Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2021
2Dronabinol (THC)FDA LinkGeneric
01/2018 - 06/2017
2Norepinephrine (Noradrenaline)FDA LinkGeneric
01/2016 - 06/2013
2Methylphenidate (Ritalin)FDA LinkGeneric
09/2013 - 11/2012
2Dextroamphetamine (Dexedrine)FDA LinkGeneric
06/2013 - 05/2010
1Ethanol (Ethyl Alcohol)IBA
04/2021
1Oxycodone (Oxycontin)FDA LinkGeneric
01/2021
1Levetiracetam (Keppra)FDA LinkGeneric
01/2021
1MicroRNAs (MicroRNA)IBA
01/2021
1Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
12/2020
1Cholinergic Agents (Cholinergics)IBA
12/2020
1phendimetrazine (Bontril)FDA LinkGeneric
01/2020
1VU0652957IBA
03/2019
1Anti-Bacterial Agents (Antibiotics)IBA
04/2018
1Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
04/2018
1Biomarkers (Surrogate Marker)IBA
11/2016
1Estradiol (Delestrogen)FDA LinkGeneric
04/2016
12- (N- cyclopropylmethyl- 4,5- epoxy- 6,14- ethano- 3- hydroxy- 6- methoxymorphinan- 7- yl)- 3,3- dimethylpentan- 2- olIBA
01/2016
1Buspirone (Buspar)FDA LinkGeneric
04/2015
1Dopamine Receptors (Dopamine Receptor)IBA
03/2015
1Antipsychotic Agents (Antipsychotics)IBA
01/2015
1Quetiapine Fumarate (Seroquel)FDA Link
01/2015
1Methamphetamine (Desoxyn)FDA LinkGeneric
10/2012
1Neurotransmitter Agents (Neurotransmitter)IBA
01/2012
1Varenicline (Chantix)FDA Link
11/2011
1Opioid Analgesics (Opioids)IBA
05/2010
1Dopamine Agonists (Dopamine Agonist)IBA
05/2010
1NGB 2904IBA
05/2007
1fluoreneIBA
05/2007
1N- (4- (4- (2,3- dichlorophenyl)piperazin- 1- yl)butyl)- 4- (pyridin- 2- yl)benzamideIBA
05/2007
1benzamideIBA
05/2007
1Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
08/2005
1Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
07/2004
1Biological ProductsIBA
02/2002

Therapy/Procedure

6Self Administration (Administration, Self)
09/2014 - 11/2002
3Drug Therapy (Chemotherapy)
01/2021 - 08/2014
2Therapeutics
01/2015 - 07/2004
1Euthanasia (Mercy Killing)
04/2018